Testing effectiveness (Phase 2)Study completedNCT03205163
What this trial is testing
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Who this might be right for
Hemophilia A
Bioverativ, a Sanofi company 16